Loading
Life sciences · Journal article
Experimental and Molecular Pathology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer immunotherapy has revolutionized oncology by improving therapeutic specificity and efficacy, leading to major clinical successes. Among these approaches, chimeric antigen receptor (CAR-T) cell therapy has shown remarkable results in hematological malignancies. However, its effectiveness in solid tumors is limited by antigen heterogeneity, poor tumor infiltration, and the immunosuppressive tumor microenvironment (TME). To address these limitations, combining CAR-T therapy with oncolytic viruses (OVs) has gained increasing attention. OVs selectively infect and lyse tumor cells while simultaneously stimulating innate and adaptive antitumor immune responses through enhanced antigen release and inflammatory signaling, thereby modulating the TME and enhancing antigen presentation. Evidence from preclinical studies and early clinical trials indicates that CAR-T and OV combination therapy can generate synergistic antitumor effects by improving immune cell infiltration, enhancing cytotoxic activity, and reducing immune evasion. This review highlights recent Advances in the engineering of CAR-T cells and OVs and their synergistic potential in the treatment of solid tumors.